Survey respondents agree that participating in clinical trials improved their overall quality of care
RESEARCH TRIANGLE PARK, N.C. - Friday, October 30th 2015 [ME NewsWire]
(BUSINESS WIRE)-- Quintiles, the world’s largest provider of product development and integrated healthcare services, today published new research that reveals high levels of patient satisfaction and engagement in clinical research. Based on a survey of U.S. clinical research patients, all of the respondents agreed that clinical research participation reduced their overall cost of healthcare and improved their interest/involvement in their overall health.
In addition, 95 percent of survey participants said that participating in clinical research positively impacted their overall quality of care.
“These findings illustrate the value of integrating clinical research into the traditional continuum of care,” said Jeanne Hecht, senior vice president, Site & Patient Networks at Quintiles. “It is imperative that we continue to prioritize and support the patient and physician experience in clinical research. Coupled with high-quality processes, this support enables the right physician to connect the right patient to the right trial.”
In this survey, participants were patients with type II diabetes involved in an ongoing diabetes clinical trial. The clinical trial is scheduled to continue for four years, and participants will be surveyed annually until the conclusion of the clinical trial.
To learn more about this research, download Quintiles’ new paper, “Clinical Research Participation as a Care Option.” The paper is co-authored by experts from the global biopharmaceutical and research industries.
This research will be discussed at Quintiles’ inaugural Site Vision Forum on October 29-30, 2015 in Charlotte, N.C. The interactive event will bring together sites to discuss key trends and identify areas for increased collaboration and support. Quintiles will host a second Site Vision Forum in Europe this December.
About Quintiles
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Contacts
Quintiles
Media Relations:
Phil Bridges, + 1-919-998-1653
Mobile: +1-919-457-6347
phil.bridges@quintiles.com
Investor Relations:
Todd Kasper, +1-919-998-2590
InvestorRelations@quintiles.com
Permalink: http://www.me-newswire.net/news/16211/en
RESEARCH TRIANGLE PARK, N.C. - Friday, October 30th 2015 [ME NewsWire]
(BUSINESS WIRE)-- Quintiles, the world’s largest provider of product development and integrated healthcare services, today published new research that reveals high levels of patient satisfaction and engagement in clinical research. Based on a survey of U.S. clinical research patients, all of the respondents agreed that clinical research participation reduced their overall cost of healthcare and improved their interest/involvement in their overall health.
In addition, 95 percent of survey participants said that participating in clinical research positively impacted their overall quality of care.
“These findings illustrate the value of integrating clinical research into the traditional continuum of care,” said Jeanne Hecht, senior vice president, Site & Patient Networks at Quintiles. “It is imperative that we continue to prioritize and support the patient and physician experience in clinical research. Coupled with high-quality processes, this support enables the right physician to connect the right patient to the right trial.”
In this survey, participants were patients with type II diabetes involved in an ongoing diabetes clinical trial. The clinical trial is scheduled to continue for four years, and participants will be surveyed annually until the conclusion of the clinical trial.
To learn more about this research, download Quintiles’ new paper, “Clinical Research Participation as a Care Option.” The paper is co-authored by experts from the global biopharmaceutical and research industries.
This research will be discussed at Quintiles’ inaugural Site Vision Forum on October 29-30, 2015 in Charlotte, N.C. The interactive event will bring together sites to discuss key trends and identify areas for increased collaboration and support. Quintiles will host a second Site Vision Forum in Europe this December.
About Quintiles
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Contacts
Quintiles
Media Relations:
Phil Bridges, + 1-919-998-1653
Mobile: +1-919-457-6347
phil.bridges@quintiles.com
Investor Relations:
Todd Kasper, +1-919-998-2590
InvestorRelations@quintiles.com
Permalink: http://www.me-newswire.net/news/16211/en
No comments:
Post a Comment